 All right. Thank you. Okay. Good afternoon, everyone. And so, yeah, I will be giving an update on G-TEX, the Genotype and Tissue Expression Program. So, G-TEX is the NNIH Common Fund Program, and the co-chairs are Dr. Green and Dr. Insel. The two leading IC are NHGRI and NIMH. NCI has played a very important role in this project as well. We have a very engaged working group at the NNIH, which has a lot of people, a lot of members from different ICs. So, the goal of G-TEX is to establish a resource database and tissue bank in which we study the relationship between genetic variation and gene expression in reference known disease human tissues. Right now we are collecting over 30 tissues in a rapid autopsy setting, and we are performing RNA sequencing on all the samples that are of enough good quality. And while we expect at some point to probably do some sequencing of the blood DNA, we are right now performing high-density SNP genotyping and with the Lumina 5M as well as an exome chip. So, G-TEX has started as a pilot in 2010 and last year as a pilot in 2012, and their recruitment and RNA quality goals, which were the main concern for full implementation of this program, were met. The goal for recruitment, for example, was to be able to enroll at least 10 donors by the end of the pilot, by the end of the month of the pilot. And as you can see from this graph really, which shows the number of donors by month, we were able to achieve this goal on average. And the RNA quality goals, which I mentioned before, were met as well as measured by the RIN values. G-TEX, at the end of the scale-up, we can imagine being a resource which will provide really an atlas of human gene expression, in addition to provide a comprehensive CIS and trans-EQTL result for each tissues. The resource, at the end, will include around 900 post-mortem donors, completely genotyped. We are expecting to collect over 25,000 tissues, and being able to hopefully perform RNA sequencing on almost all of them. We are also expecting to have associated clinical and histopathological data available for the samples, and being able to provide a system to access both data and samples. We are also performing an analysis study of donors' family, and results from that study will be available as well. Well, G-TEX is a very complex program and has a lot of moving parts. So I'm going to go briefly over the component of G-TEX. Organ donors' enrollment is done through organ procurement organization and tissue banks. We have right now two sites that are enrolling donors. We have a sample and a data repository. We have a very highly engaged team of pathologists which are reviewing each sample they receive. These activities are coordinated and managed by NCI through the CA Hub initiative. We have also a brain bank where the brains that are collected at the source sites go and their further dissection of the brain happens. We have a centralized laboratory and data analysis and coordinating center. This is the Broad Institute. This place really does a lot of things, among which performs the RNA sequencing, the SNP genotyping, takes care of coordinating this project and also performs data analysis. Together we actually a very engaged group of geneticists, statistical geneticists, and they basically tackle the data that have been generated by G-TEX. We also have, as I mentioned before, in-house study that is happening, and NCBI is managing the G-TEX database and the EQTL browser. In addition to this, we are planning to add a new component which is the enhanced G-TEX. I will talk a little bit more about this later on in this presentation. Let's look at the data that are available from G-TEX. G-TEX data are housed in two places. We have DBGAP, which has the control access data, such as SNP genotyping files, as well as BAM files from RNA site. But we envision to be this place also an archive sometimes in the future of all the G-TEX data. We have then another place where G-TEX data are available, and that is the G-TEX portal. It is housed at the Brody Institute, this is the URL, and this has been designed with a different goal in mind. More as a place where user can go and use the features that are available there in a user-friendly way. There are several ways the user can look at the data, display the data, search the data. In fact, we have an option here where there is a tab where they can go to the next page and can search, for example, EQTLs, either by gene or by SNP, and this is also the place where other features are available and I'll talk a little bit more later. So look at the expression data production and release. This is a graph that shows the number of cases analyzed and deposited into the big app by organ site. This is a list of organs that is, it's not the full list that we have. In the red box I have highlighted the brain areas, and as you can see here in the dark blue bars we have the number of cases deposited since last November. We also have in the light blue bars cases that will be deposited by the end of this month and the very light blue bars indicates the remaining of the pilot. So if you look at the overall you can notice that basically by the end of the pilot we will have the data set of the pilot basically will include seven sites with at least 100 donors and two sites with at least 90 donors each. In the scale up we are planning to sequence all the samples that are coming in of enough good quality and performing hopefully our DNA sequencing of the blood samples or at least the chips that we are actually doing right now. So I told you a little bit more about the data that are available. Let's look at the samples now. What do we have? GTACS has a tissue that has been Pax gene fixed and frozen. We have also Pax gene fixed tissues which has been paraffin embedded and stored and we have also some nucleic acid. We have nucleic acid. The brain is the only organ that has not been Pax gene fixed but has been it is shipped on ice from the sort site to the brain bank. At the brain bank the group there further dissect the brain into 1.5 centimeter slabs and then those additional area together with the remaining of the brain are flesh frozen and stored. We also have cell lines available. We have lymphoblastoid and fibroblasts cell lines. Lymphoblastoid cell lines are successful right now for 50% of the donors where in staff fibroblasts they have a higher success rate. Here you see another search capability of the portal at the Broad Institute where a user can go after logging in and search for samples, basically search the inventory at the Broad. They can look at the different material, different tissue site and do kind of mind what is available for GTACS. So now how did we how are we making these samples available? Well last November the NIH issued an RFA the enhanced GTACS with molecular analysis of stored biospecimen RFA. This RFA has a receipt date of March 28. We expect to have a summer review done by CSR. Those applications will come to this council next September for funding in early FY14. So you will see those applications and the common fund gave us 10 million dollars over three years with 3.8 in FY14. So the goal of this RFA it's really to it's open. It's open to the most compelling ideas. We really want the scientists to leverage the uniqueness of GTACS and come up with ways how to add value to this resource. So with this I would like to thank all the institution that are part of this project for the great support in achieving the goals we had and I will be happy to take questions. Sure. Could you speak just a little bit to what LC project is like that's part of this? Sure. The LC project is really looking at the next of kin how you know the family has felt about the process of consenting for this program. There are there is a group at University of Virginia Commonwealth that is highly engaged in this and so we had the donors of families interviewed after and asked questions about the consent process. How they felt? Did they understand the process? Did they understand what the study was about? There are a lot of questions that we ask them and we try to incorporate their suggestions in the review that we do to the consent process as well. Could I ask a little bit about the ascertainment? What's your acceptance and your rejection criteria for donors? So donors are the we have a few very few criteria. Donors age has to be between 21 and 70 years old. We have a limit on the BMI between 18 and 35 and the donors have to donors have to be free of major disease among which concern. One of the exclusion criteria for example is that they couldn't receive chemotherapy the last couple of years and we also have to think about how these donors get to GTAC. So these donors are mainly recruited through organ procurement organization. So the criteria that stand for those basically stand also for GTACs. These are organ transplant cases. Most of the cases are. Some are autopsy rapid autopsy cases. Do you find yourself sometimes in conflict with the organ procurement process? Well this case goes first to organ procurement organization. So if they qualify for that then they pass and become GTACs cases. Okay thank you very much Simona.